Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy

Cheng Kun Du, Dong Yun Zhan, Sachio Morimoto, Tsuyoshi Akiyama, Daryl O. Schwenke, Hiroshi Hosoda, Kenji Kangawa, Mikiyasu Shirai

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Although ghrelin has been demonstrated to improve cardiac function in heart failure, its therapeutic efficacy on the life expectancy remains unknown. We aim to examine whether ghrelin can improve the life survival in heart failure using a mouse model of inherited dilated cardiomyopathy (DCM) caused by a deletion mutation ΔK210 in cardiac troponin T (cTnT). From 30 days of age, ghrelin (150 μg/kg) was administered subcutaneously to DCM mice once daily, control mice received saline only. The survival rates were compared between the two groups for 30 days. After 30-day treatment, functional and morphological measurements were conducted. Ghrelin-treated DCM mice had significantly prolonged life spans compared with saline-treated control DCM mice. Echocardiography showed that ghrelin reduced left ventricular (LV) end-diastolic dimensions and increased LV ejection fraction. Moreover, histoanatomical data revealed that ghrelin decreased the heart-to-body weight ratio, prevented cardiac remodeling and fibrosis, and markedly decreased the expression of brain natriuretic peptide. Telemetry recording and heart rate variability analysis showed that ghrelin suppressed the excessive cardiac sympathetic nerve activity (CSNA) and recovered the cardiac parasympathetic nerve activity. These results suggest that ghrelin has therapeutic benefits for survival as well as for the cardiac function and remodeling in heart failure probably through suppression of CSNA and recovery of cardiac parasympathetic nerve activity.

Original languageEnglish
Article numbere00064
JournalPharmacology Research and Perspectives
Volume2
Issue number5
DOIs
Publication statusPublished - Oct 2014

Fingerprint

Ghrelin
Dilated Cardiomyopathy
Heart Failure
Telemetry
Troponin T
Sequence Deletion
Brain Natriuretic Peptide
Life Expectancy
Stroke Volume
Echocardiography
Fibrosis
Survival Rate
Heart Rate
Body Weight
Therapeutics

All Science Journal Classification (ASJC) codes

  • Neurology
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Du, C. K., Zhan, D. Y., Morimoto, S., Akiyama, T., Schwenke, D. O., Hosoda, H., ... Shirai, M. (2014). Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. Pharmacology Research and Perspectives, 2(5), [e00064]. https://doi.org/10.1002/prp2.64

Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. / Du, Cheng Kun; Zhan, Dong Yun; Morimoto, Sachio; Akiyama, Tsuyoshi; Schwenke, Daryl O.; Hosoda, Hiroshi; Kangawa, Kenji; Shirai, Mikiyasu.

In: Pharmacology Research and Perspectives, Vol. 2, No. 5, e00064, 10.2014.

Research output: Contribution to journalArticle

Du, CK, Zhan, DY, Morimoto, S, Akiyama, T, Schwenke, DO, Hosoda, H, Kangawa, K & Shirai, M 2014, 'Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy', Pharmacology Research and Perspectives, vol. 2, no. 5, e00064. https://doi.org/10.1002/prp2.64
Du, Cheng Kun ; Zhan, Dong Yun ; Morimoto, Sachio ; Akiyama, Tsuyoshi ; Schwenke, Daryl O. ; Hosoda, Hiroshi ; Kangawa, Kenji ; Shirai, Mikiyasu. / Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy. In: Pharmacology Research and Perspectives. 2014 ; Vol. 2, No. 5.
@article{391b14483039490eb9657d3b1be4b267,
title = "Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy",
abstract = "Although ghrelin has been demonstrated to improve cardiac function in heart failure, its therapeutic efficacy on the life expectancy remains unknown. We aim to examine whether ghrelin can improve the life survival in heart failure using a mouse model of inherited dilated cardiomyopathy (DCM) caused by a deletion mutation ΔK210 in cardiac troponin T (cTnT). From 30 days of age, ghrelin (150 μg/kg) was administered subcutaneously to DCM mice once daily, control mice received saline only. The survival rates were compared between the two groups for 30 days. After 30-day treatment, functional and morphological measurements were conducted. Ghrelin-treated DCM mice had significantly prolonged life spans compared with saline-treated control DCM mice. Echocardiography showed that ghrelin reduced left ventricular (LV) end-diastolic dimensions and increased LV ejection fraction. Moreover, histoanatomical data revealed that ghrelin decreased the heart-to-body weight ratio, prevented cardiac remodeling and fibrosis, and markedly decreased the expression of brain natriuretic peptide. Telemetry recording and heart rate variability analysis showed that ghrelin suppressed the excessive cardiac sympathetic nerve activity (CSNA) and recovered the cardiac parasympathetic nerve activity. These results suggest that ghrelin has therapeutic benefits for survival as well as for the cardiac function and remodeling in heart failure probably through suppression of CSNA and recovery of cardiac parasympathetic nerve activity.",
author = "Du, {Cheng Kun} and Zhan, {Dong Yun} and Sachio Morimoto and Tsuyoshi Akiyama and Schwenke, {Daryl O.} and Hiroshi Hosoda and Kenji Kangawa and Mikiyasu Shirai",
year = "2014",
month = "10",
doi = "10.1002/prp2.64",
language = "English",
volume = "2",
journal = "Pharmacology Research and Perspectives",
issn = "2052-1707",
publisher = "Wiley-Blackwell Publishing Ltd",
number = "5",

}

TY - JOUR

T1 - Survival benefit of ghrelin in the heart failure due to dilated cardiomyopathy

AU - Du, Cheng Kun

AU - Zhan, Dong Yun

AU - Morimoto, Sachio

AU - Akiyama, Tsuyoshi

AU - Schwenke, Daryl O.

AU - Hosoda, Hiroshi

AU - Kangawa, Kenji

AU - Shirai, Mikiyasu

PY - 2014/10

Y1 - 2014/10

N2 - Although ghrelin has been demonstrated to improve cardiac function in heart failure, its therapeutic efficacy on the life expectancy remains unknown. We aim to examine whether ghrelin can improve the life survival in heart failure using a mouse model of inherited dilated cardiomyopathy (DCM) caused by a deletion mutation ΔK210 in cardiac troponin T (cTnT). From 30 days of age, ghrelin (150 μg/kg) was administered subcutaneously to DCM mice once daily, control mice received saline only. The survival rates were compared between the two groups for 30 days. After 30-day treatment, functional and morphological measurements were conducted. Ghrelin-treated DCM mice had significantly prolonged life spans compared with saline-treated control DCM mice. Echocardiography showed that ghrelin reduced left ventricular (LV) end-diastolic dimensions and increased LV ejection fraction. Moreover, histoanatomical data revealed that ghrelin decreased the heart-to-body weight ratio, prevented cardiac remodeling and fibrosis, and markedly decreased the expression of brain natriuretic peptide. Telemetry recording and heart rate variability analysis showed that ghrelin suppressed the excessive cardiac sympathetic nerve activity (CSNA) and recovered the cardiac parasympathetic nerve activity. These results suggest that ghrelin has therapeutic benefits for survival as well as for the cardiac function and remodeling in heart failure probably through suppression of CSNA and recovery of cardiac parasympathetic nerve activity.

AB - Although ghrelin has been demonstrated to improve cardiac function in heart failure, its therapeutic efficacy on the life expectancy remains unknown. We aim to examine whether ghrelin can improve the life survival in heart failure using a mouse model of inherited dilated cardiomyopathy (DCM) caused by a deletion mutation ΔK210 in cardiac troponin T (cTnT). From 30 days of age, ghrelin (150 μg/kg) was administered subcutaneously to DCM mice once daily, control mice received saline only. The survival rates were compared between the two groups for 30 days. After 30-day treatment, functional and morphological measurements were conducted. Ghrelin-treated DCM mice had significantly prolonged life spans compared with saline-treated control DCM mice. Echocardiography showed that ghrelin reduced left ventricular (LV) end-diastolic dimensions and increased LV ejection fraction. Moreover, histoanatomical data revealed that ghrelin decreased the heart-to-body weight ratio, prevented cardiac remodeling and fibrosis, and markedly decreased the expression of brain natriuretic peptide. Telemetry recording and heart rate variability analysis showed that ghrelin suppressed the excessive cardiac sympathetic nerve activity (CSNA) and recovered the cardiac parasympathetic nerve activity. These results suggest that ghrelin has therapeutic benefits for survival as well as for the cardiac function and remodeling in heart failure probably through suppression of CSNA and recovery of cardiac parasympathetic nerve activity.

UR - http://www.scopus.com/inward/record.url?scp=84992196327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84992196327&partnerID=8YFLogxK

U2 - 10.1002/prp2.64

DO - 10.1002/prp2.64

M3 - Article

AN - SCOPUS:84992196327

VL - 2

JO - Pharmacology Research and Perspectives

JF - Pharmacology Research and Perspectives

SN - 2052-1707

IS - 5

M1 - e00064

ER -